Science Corporation has raised $400 million in Series D funding, bringing the brain-tech company’s valuation to $3.5 billion. The new capital is expected to help the company scale its anti-blindness business and accelerate work on technologies designed to address severe vision loss.
The raise is a strong signal of investor confidence in neurotechnology that can deliver real-world health and accessibility benefits. For people affected by blindness or major visual impairment, advances in brain and vision interfaces could eventually open new paths toward independence and improved quality of life.
Why this matters
- Major funding: A $400 million round gives Science Corp significant resources to grow.
- Accessibility impact: The company’s focus on anti-blindness technology targets a life-changing medical need.
- Momentum for brain tech: A $3.5 billion valuation highlights growing confidence in neurotechnology’s future.
While the story is centered on financing, the broader win is the continued movement of advanced brain and vision technology from research toward scalable products. If successful, this kind of innovation could help bring transformative assistive technology to more people.